X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4016) 4016
Publication (244) 244
Book Review (47) 47
Book Chapter (25) 25
Dissertation (4) 4
Conference Proceeding (2) 2
Book / eBook (1) 1
Data Set (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2662) 2662
humans (2515) 2515
diabetes mellitus, type 2 - drug therapy (1834) 1834
type 2 diabetes (1501) 1501
male (1417) 1417
endocrinology & metabolism (1375) 1375
dipeptidyl-peptidase iv inhibitors - therapeutic use (1230) 1230
diabetes (1210) 1210
dipeptidyl peptidase-4 inhibitor (1181) 1181
hypoglycemic agents - therapeutic use (1163) 1163
female (1092) 1092
glucagon-like peptide-1 (1013) 1013
middle aged (896) 896
animals (894) 894
sitagliptin (882) 882
dipeptidyl peptidase-4 inhibitors (848) 848
pharmacology & pharmacy (773) 773
aged (733) 733
glucose (713) 713
metformin (678) 678
double-blind (676) 676
glycemic control (644) 644
treatment outcome (619) 619
dipeptidyl-peptidase iv inhibitors - pharmacology (613) 613
diabetes mellitus, type 2 - blood (596) 596
diabetes mellitus (578) 578
insulin (571) 571
hypoglycemic agents (556) 556
hypoglycemic agents - adverse effects (526) 526
dipeptidyl-peptidase iv inhibitors - adverse effects (525) 525
adult (508) 508
type 2 diabetes mellitus (487) 487
safety (477) 477
blood glucose - metabolism (469) 469
care and treatment (469) 469
type-2 diabetes-mellitus (469) 469
adamantane - analogs & derivatives (458) 458
vildagliptin (450) 450
drug therapy, combination (448) 448
efficacy (438) 438
analysis (430) 430
blood glucose - drug effects (428) 428
drug therapy (428) 428
dipeptidyl peptidase-4 (416) 416
internal medicine (415) 415
sitagliptin phosphate (413) 413
risk factors (412) 412
hypoglycemic agents - administration & dosage (409) 409
dipeptidyl peptidase 4 - metabolism (406) 406
research (396) 396
hypoglycemic agents - pharmacology (389) 389
beta-cell function (380) 380
mice (373) 373
dipeptidyl-peptidase iv inhibitors - administration & dosage (366) 366
diabetes therapy (363) 363
medicine, general & internal (361) 361
dpp-4 inhibitor (354) 354
glucagon (345) 345
dextrose (340) 340
medicine & public health (339) 339
metformin - therapeutic use (336) 336
linagliptin (333) 333
glycated hemoglobin a - metabolism (332) 332
diabetes mellitus, type 2 - complications (330) 330
improves glycemic control (320) 320
mellitus (320) 320
peptidase (317) 317
hyperglycemia (311) 311
glp-1 (307) 307
insulin resistance (306) 306
rats (303) 303
double-blind method (280) 280
hypoglycemia (280) 280
adamantane - therapeutic use (279) 279
clinical trials (279) 279
diabetes mellitus, type 2 - metabolism (276) 276
therapy (272) 272
peptides (271) 271
dosage and administration (265) 265
health aspects (263) 263
cardiac & cardiovascular systems (255) 255
triazoles - therapeutic use (254) 254
dpp-4 inhibitors (253) 253
pyrazines - therapeutic use (251) 251
abridged index medicus (250) 250
medicine, research & experimental (250) 250
incretin (243) 243
saxagliptin (235) 235
obesity (227) 227
review (224) 224
studies (224) 224
pharmacokinetics (222) 222
risk (221) 221
inflammation (218) 218
oxidative stress (216) 216
glycosylated hemoglobin (206) 206
diabetes mellitus, type 2 - physiopathology (205) 205
monotherapy (202) 202
drug-naive patients (201) 201
incretins - therapeutic use (201) 201
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3885) 3885
German (27) 27
Japanese (25) 25
French (24) 24
Korean (20) 20
Russian (14) 14
Spanish (14) 14
Hungarian (8) 8
Chinese (4) 4
Italian (4) 4
Czech (1) 1
Danish (1) 1
Dutch (1) 1
Polish (1) 1
Slovenian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
The Lancet, ISSN 0140-6736, 2006, Volume 368, Issue 9548, pp. 1696 - 1705
Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that stimulates insulin and suppresses glucagon secretion, inhibits gastric emptying, and... 
MEDICINE, GENERAL & INTERNAL | IN-VITRO | METFORMIN-TREATED PATIENTS | HEALTHY-SUBJECTS | 2ND-PHASE INSULIN-SECRETION | IMPROVES GLYCEMIC CONTROL | BETA-CELL APOPTOSIS | IV INHIBITOR | 7-36 AMIDE | IMPROVED GLUCOSE-TOLERANCE | EXENATIDE SYNTHETIC EXENDIN-4 | Triazoles - administration & dosage | Triazoles - adverse effects | Glucagon-Like Peptide 1 - administration & dosage | Humans | Pyrazines - administration & dosage | Glucagon-Like Peptide 1 - biosynthesis | Dipeptidyl Peptidase 4 | Glucagon-Like Peptide 1 - physiology | Pyrazines - therapeutic use | Adenosine Deaminase Inhibitors | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Adamantane - therapeutic use | Pyrrolidines | Venoms - administration & dosage | Nitriles | Sitagliptin Phosphate | Adamantane - administration & dosage | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Glucagon-Like Peptide 1 - classification | Hypoglycemic Agents - therapeutic use | Receptors, Glucagon - agonists | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Glycoproteins - antagonists & inhibitors | Clinical Trials as Topic | Glucagon-Like Peptide-1 Receptor | Dipeptidyl-Peptidase IV Inhibitors | Pyrazines - adverse effects | Venoms - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Liraglutide | Peptides - adverse effects | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Care and treatment | Diagnosis | Glucagon | Analysis | Dosage and administration | Research | Protease inhibitors | Drug therapy | Proteins | Diabetes | Kinases | Insulin | Rodents
Journal Article